My postcode meant I was denied free access to a life-saving treatment
For years, where a man with aggressive prostate cancer happened to live in Britain determined whether he could access a drug that might keep him alive — a quiet injustice embedded in the architecture of public health. This week, NHS England moved to close that gap, extending access to abiraterone to thousands of men whose cancer is high-risk but has not yet spread. The decision, grounded in compelling trial data and driven by patient advocates and bereaved families, reflects a broader reckoning with how geography should never be destiny when lives are at stake.
- Men in England with high-risk prostate cancer were being denied a life-extending drug freely available to patients in Scotland and Wales, creating a postcode lottery with lethal consequences.
- Clinical trial data showed abiraterone cuts recurrence risk by half and reduces the chance of death by 40%, making the case for expansion not just compelling but morally urgent.
- Prostate Cancer UK, MPs, and patients who had paid privately for the drug mounted a sustained campaign to force the policy change, turning individual suffering into collective pressure.
- NHS England has now approved abiraterone for roughly 9,000 men per year at the high-risk, non-metastatic stage — with 2,000 already diagnosed becoming eligible immediately.
- Over the next five years, the NHS estimates nearly 8,000 men will be spared a recurrence diagnosis and approximately 3,000 lives will be saved — while fewer recurrences also reduce long-term NHS costs.
For years, a man in England diagnosed with aggressive prostate cancer faced a bitter reality: the same drug available free to patients in Scotland and Wales required private payment south of the border. That inequity has now ended. NHS England announced this week that abiraterone — a hormone therapy that suppresses testosterone production — will be offered to men whose prostate cancer is high-risk but has not yet metastasized, reaching around 9,000 men annually.
The evidence driving the change came from the Stampede trial, led by Professor Nick James at the Institute of Cancer Research. Its findings were striking: two years on abiraterone halved the risk of recurrence and cut the risk of death by 40 percent. At six years, 86 percent of men on the drug were alive, compared to 77 percent on standard treatment. The NHS estimates that over the next five years, nearly 8,000 men will be spared the news that their cancer has returned, and around 3,000 lives will be saved.
Giles Turner, 65, from Brighton, paid privately for abiraterone after his 2023 diagnosis and is now in remission. Learning that his postcode had denied him free access to a potentially life-saving treatment left him stunned. His experience became part of a wider campaign by Prostate Cancer UK and MPs including Labour's Rupa Huq, whose own father died of the disease.
Professor Peter Johnson of NHS England described the expansion as potentially life-changing for thousands of men. Beyond the human toll, there is a financial rationale too: fewer recurrences mean less intensive treatment further down the line, compounding savings for the health service over time. The drug will be available within weeks — the closing of a gap that, for those who lived through it, should never have existed at all.
For years, a man in England diagnosed with aggressive prostate cancer faced a cruel arithmetic: the drug that could save his life was available to his counterpart in Scotland or Wales, but not to him. That gap has closed. NHS England announced this week that abiraterone, a hormone therapy that blocks testosterone production throughout the body, will now be available to men whose prostate cancer is high-risk but has not yet spread. The expansion means roughly 2,000 men diagnosed in the past three months will become eligible immediately, with another 7,000 per year likely to qualify going forward.
Until now, abiraterone was reserved for patients whose cancer had already metastasized—a narrower population, a later stage of disease. The evidence that prompted the change came from the Stampede trial, led by Professor Nick James at the Institute of Cancer Research in London. The data showed something stark: men who took abiraterone for two years cut their risk of cancer recurrence in half. Their risk of death fell by 40 percent. Over six years, 86 percent of men on abiraterone were alive, compared to 77 percent on standard hormone therapy with or without radiotherapy. In the next five years, the NHS estimates, nearly 8,000 men will be spared the news that their cancer has returned.
Giles Turner, 65, from Brighton, knows what that reprieve means. Diagnosed with aggressive prostate cancer in March 2023, he paid for abiraterone privately and is now in remission. When he learned the drug was available on the NHS in Scotland and Wales but not in England, he was stunned. "My postcode meant I was denied free access to a treatment that could halve my risk of dying," he said. That postcode lottery—the randomness of where you lived determining whether you could afford a life-extending drug—became the focal point of a campaign by Prostate Cancer UK and MPs including Labour's Rupa Huq, whose father died of prostate cancer.
The clinical case was always strong. What changed was the willingness to act on it. Professor Peter Johnson, the national clinical director for cancer at NHS England, framed the decision in terms of what it offers patients: "For thousands of men with prostate cancer, this treatment option could be life-changing by helping keep their cancer at bay for several years." Amy Rylance, assistant director of health improvement at Prostate Cancer UK, called it a "momentous, life-saving victory." The organization calculated that 3,000 lives will be saved over the next five years.
There is also a financial logic at work. Professor James noted that fewer recurrences mean fewer men requiring intensive treatment down the line—a saving for the NHS that compounds over time. The drug will be available within weeks. For men who have lived with the terror of a diagnosis they could not afford to treat, the expansion represents something more than a policy shift. It is the closing of a gap that should never have existed in the first place.
Notable Quotes
Two years of abiraterone halves the risk of prostate cancer coming back and reduces risk of death by 40%— Professor Nick James, Institute of Cancer Research
This decision is a momentous, life-saving victory for the thousands of men whose lives will now be saved— Amy Rylance, Prostate Cancer UK
The Hearth Conversation Another angle on the story
Why did it take this long? The evidence from Stampede was clear—why was abiraterone restricted to advanced cases for so long?
Access decisions move slowly, and they're often driven by cost and capacity constraints as much as by evidence. The drug works, yes, but expanding it means treating more people earlier. That's a budget conversation, not just a clinical one.
But the NHS saves money in the long run if fewer men need intensive treatment for recurrent cancer.
Exactly. That's what James emphasized. But those savings come later, and budgets are allocated now. It took a campaign—Prostate Cancer UK, MPs, patients like Giles Turner going public—to shift the political will.
What about the men who paid privately while waiting? Does this decision vindicate them or just highlight what they lost?
Both. Turner got his life back. But he had to pay for it. Others couldn't afford to. That's the postcode lottery—it's not just unfair, it's arbitrary. A man in Cardiff got the drug free; a man in Brighton paid thousands. Same disease, same evidence, different outcome.
Is there a risk the NHS expands access too broadly now, or is this the right calibration?
They're being specific: high-risk cancer that hasn't spread yet. It's not everyone with prostate cancer. It's the population where the evidence is strongest. That seems measured.
What happens to the men whose cancer does recur despite abiraterone?
They're not abandoned. James said the drug gives them more healthy years even if it doesn't prevent recurrence entirely. It's not a cure for everyone, but it's a reprieve—and sometimes that's what matters most.